Screener
Agios Pharmaceuticals AGIO Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Agios Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
FAQ
- What is Agios Pharmaceuticals's debt-to-equity?
- Agios Pharmaceuticals (AGIO) reported debt-to-equity of 0× in Q2 2026.
- How has Agios Pharmaceuticals's debt-to-equity changed year-over-year?
- Agios Pharmaceuticals's debt-to-equity decreased by 14.6% year-over-year, from 0× to 0×.
- What is the long-term trend for Agios Pharmaceuticals's debt-to-equity?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's debt-to-equity has grown at a -33.7% compound annual growth rate (CAGR), from 0.3× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Agios Pharmaceuticals's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude